Printer Friendly
The Free Library
14,680,183 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

3i and Orthovita Announce a Global Strategic Alliance.


MALVERN, Pa.--(BW HealthWire)--May 8, 1998--Implant Innovations, Inc. ("3i") and Orthovita, Inc. announced today a strategic alliance for the sale and marketing of BIOGRAN, Orthovita's proprietary synthetic bone graft bone graft Orthopedic surgery Sterilized bony tissue, often of cadaveric origin, used to fill and/or 'sculpt' bone defects Indications Spinal fusion, revision of failed articular prostheses, filling traumatic or malignant bone defects, or periodontal defects.  material. This strategic alliance combines the biomaterial biomaterial /bio·ma·te·ri·al/ (bi?o-mah-ter´e-al) a synthetic dressing with selective barrier properties, used in the treatment of burns; it consists of a liquid solvent (polyethylene glycol-400) and a powdered polymer.  technology expertise of Orthovita with 3i's expertise in dental implants and regenerative re·gen·er·a·tive  
adj.
1. Of, relating to, or marked by regeneration.

2. Tending to regenerate.



re·gen
 membrane products used in dental surgical applications.

"This strategic alliance with Orthovita will allow clinicians involved in oral reconstruction to use one source for a complete group of products. 3i dental implant products, Gore regenerative materials and Orthovita bone grafting Bone Grafting Definition

Bone grafting is a surgical procedure by which new bone or a replacement material is placed into spaces between or around broken bone (fractures) or holes in bone (defects) to aid in healing.
 products are the leading technologies in their field and 3i is pleased to be able to offer all of them to clinicians worldwide," said Keith Beaty, President and Chief Executive Officer of 3i.

"Aligning with 3i in the oral reconstruction market is the optimal way to further expand our market leadership position in synthetic dental bone grafts," said David Joseph, Orthovita President and Chief Executive Officer.

In addition to distribution rights worldwide for BIOGRAN, 3i will have the opportunity to commercialize other advanced biomaterials that are under development at Orthovita for indications related to oral reconstruction.

Orthovita is a biomaterials company focused on developing and commercializing a range of advanced bone substitutes which target four markets, including oral and cranial-maxillofacial reconstruction, orthopedic trauma, spine, and orthopedic implant fixation materials. The company, formed in 1993, is based in Malvern, Pennsylvania Malvern is a borough in Chester County, Pennsylvania, United States. The population was 3,059 at the 2000 census. Geography
Malvern is located at  (40.034557, -75.514396).
.

3i, formed in 1987 and based in Palm Beach Gardens, Florida Palm Beach Gardens is a city in Palm Beach County in the U.S. state of Florida. The city is in the center of a rapidly-developing area north of West Palm Beach in the northern part of the county and the South Florida metropolitan area. , is involved in the manufacture, marketing and sale of dental implant products and oral health products worldwide.

CONTACT: LMInformation

Lisa Easley, 617/722-0019, x137
COPYRIGHT 1998 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1998, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:May 8, 1998
Words:263
Previous Article:REPEAT: Nuevo Energy's Outlk Revised to Negative.
Next Article:ECCS Announces Call Home Features and Software To Ease Migration of Open Systems Data.
Topics:



Related Articles
Orthovita granted six new patents -- Intellectual property expands to 15 patents.
Corporate Profile for Orthovita Inc., dated Aug. 8, 1997.
Orthovita Plans an EASDAQ IPO.
Orthovita and Howmedica in Corporate Alliance Global Rights For New Generation Implant Cement.
Orthovita Announces European Initial Public Offering; First U.S. Company to Obtain Primary Listing on EASDAQ.
Orthovita Reports Third Quarter 1999 Financial Results.
Orthovita to Sell Biogran Dental Product Line to Implant Innovations Inc.; Company Focuses On Core Orthopaedic and Spine Opportunities.
Orthovita, Inc and Kensey Nash Corporation Announce an Agreement to Jointly Develop and Commercialize New Biomaterials-Based Spine Products.
Orthovita Enters into an Agreement with Angiotech Pharmaceuticals to Market Surgical Hemostat to Control Bleeding in Spine and Orthopedic Surgery.
Orthovita Expands VITOSS Line of Bone Repair Biomaterials with Launch of VITOSS Scaffold FOAM FLOW.

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles